Published in:
Open Access
01-12-2010 | Oral presentation
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
Authors:
J Eron, JM Livrozet, P Morlat, A Lazzarin, C Katlama, T Hawkins, T Fujiwara, R Cuffe, C Vavro, J Santiago, M Ait-Khaled, S Min, JM Yeo
Published in:
Journal of the International AIDS Society
|
Special Issue 4/2010
Login to get access
Excerpt
S/GSK1349572(572) showed potent activity in Phase 2 studies in INI-naive HIV-infected subjects and limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. VIKING is an ongoing 24-week Phase 2b pilot study assessing 572 in subjects with RAL-resistant HIV. A good antiviral response during the functional monotherapy phase (through Day 11) of this pilot study was observed with a strong correlation between baseline susceptibility to 572 and response. …